Myeloproliferative Neoplasms (eBook)
VIII, 240 Seiten
Springer Berlin (Verlag)
978-3-642-24989-1 (ISBN)
This book focuses on three of the main categories of myeloproliferative neoplasm: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Relevant laboratory and clinical advances are comprehensively covered, and great emphasis is placed on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic approaches, the value and limitations of mutation screening for diagnostic and prognostic purposes, risk stratification in terms of both survival and other disease complications such as leukemic transformation and thrombosis, and modern therapeutic strategies, including conventional drugs, allogeneic stem cell transplantation, and experimental drugs still under study. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.
The discovery of the JAK2 V617F mutation in the majority of patients with bcr/abl-negative myeloproliferative neoplasms has stimulated a number of questions regarding the diagnosis, prognosis, and treatment of polycythemia vera, essential thrombocythemia, and primary myelofibrosis. This book provides evidence-based reviews and expert consensus results concerning the key clinical issues for patient management. Practical recommendations are provided for the optimization and standardization of management of all three types of myeloproliferative neoplasm. Risk stratification, treatment goals, and first- and second-line therapies are discussed in detail, and other relevant diagnostic and research issues are also addressed. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.
The discovery of the JAK2 V617F mutation in the majority of patients with bcr/abl-negative myeloproliferative neoplasms has stimulated a number of questions regarding the diagnosis, prognosis, and treatment of polycythemia vera, essential thrombocythemia, and primary myelofibrosis. This book provides evidence-based reviews and expert consensus results concerning the key clinical issues for patient management. Practical recommendations are provided for the optimization and standardization of management of all three types of myeloproliferative neoplasm. Risk stratification, treatment goals, and first- and second-line therapies are discussed in detail, and other relevant diagnostic and research issues are also addressed. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.
Biology: UpdateDo we need biology studies for patient management?Gerneral Issues in the Management of MPNs:Critical Issues about the Diagnosis of MPNsPatient's Information and Examinations Needed before Planning Therapy Specific Issues of Treatment in PV and ET:Risk classificationGoal of TherapyFirst-line Therapy and Monitoring the Response in the Individual PatientPrimary and Secondary Antithrombotic ProphylaxisWhen to change Therapy: Second Line OptionsThe Evolution in Myelofibrosis and LeukemiaTreatment of PMF:Current Clinical NeedsRisk StratificationGoal of Therapy: Palliation and CurativeResearch Issues and Perspectives:New drugsOngoing Clinical TrialsHow to Design Clinical Studies in Rare Diseases
| Erscheint lt. Verlag | 10.1.2012 |
|---|---|
| Reihe/Serie | Hematologic Malignancies | Hematologic Malignancies |
| Zusatzinfo | VIII, 240 p. 22 illus., 13 illus. in color. |
| Verlagsort | Berlin |
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Innere Medizin |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| Schlagworte | Myeloproliferative • Neoplasms • polycythemia vera • Primary Myelofibrosis • Thrombocythemia |
| ISBN-10 | 3-642-24989-2 / 3642249892 |
| ISBN-13 | 978-3-642-24989-1 / 9783642249891 |
| Haben Sie eine Frage zum Produkt? |
PDF (Wasserzeichen)Größe: 5,3 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
